Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-12-06
2010-02-16
Lam, Ann Y. (Department: 1641)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C424S139100, C424S143100, C424S144100, C435S007100, C435S007210, C435S070210, C435S452000, C435S334000, C436S506000, C436S512000, C436S547000, C436S548000, C530S387300, C530S388700, C530S389300, C530S389600
Reexamination Certificate
active
07662928
ABSTRACT:
Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.
REFERENCES:
patent: 6992234 (2006-01-01), Roopenian
patent: 2002/0138863 (2002-09-01), Roopenian
patent: WO 2004035753 (2004-04-01), None
Roes et al., 1995. Mouse anti-mouse IgD monoclonal antibodies generated in IgD-deficient mice. J. Immunological Methods 183: 231-237.
Getman et al., 2005. Pharmacokinetic effects of 4C9, and anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J. Pharmaceutical Sci. 94: 718-729.
Raghavan et al., 1994. Investigation of the interaction between the class 1 MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1: 303-315.
Lampson et al., 1983. Striking paucity of HLA-A, B, C and Beta-2-microglobulin on human neuroblastoma cell lines. J. Immunol. 130: 2471-2478.
Parham et al., 1983. Arginine 45 is a major part of the antigenic determinant of human beta-2-microglobulin recognized by mouse monoclonal antibody BBM.1. J. Biol. Chem. 258: 6179-6186.
Yu et al., 1999. Mechanism of intravenous immune globulin therapy in antibody-medicated autoimmune diseases. New England Journal of Medicine 340: 227-228.
Story et al., 1994. A major histocompatibility complex class-I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 180: 2377-2381.
Bussel,Another Interaction of the FcR System with IVIG, Thromb Haemost, 2002, 88, pp. 890-891.
Hansen et al.,Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in rat module of immune thrombocytopenia, Blood, Sep. 15, 2002, V. 100, No. 6, pp. 2087-2093.
Hansen et al.,Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor, Thromb Haemost, 2002, 88, pp. 898-899.
Hansen et al.,Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Intravenous Immunoglobulin on the Disposition of Antiplatelet Antibodies in a Rat Model of Immune Thombocytopenia, Jun. 2003, V. 92, No. 6, pp. 1206-1215.
Balthasar Joseph P.
Hansen Ryan J.
Jin Feng
Grun James L
Hodgson & Russ LLP
Lam Ann Y.
The Research Foundation of State University of New York
LandOfFree
Anti-FcRn antibodies for treatment of auto/allo immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-FcRn antibodies for treatment of auto/allo immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-FcRn antibodies for treatment of auto/allo immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4198346